aTTP: Clinical Application of Precision Medicine and New Guidelines

Join us for this interactive ASH satellite symposia featuring global experts perspectives on the latest data on the management of acquired thrombotic thrombocytopenic purpura (aTTP) with the latest clinical evidence informing precision medicine, including discussion around patient cases, and the opportunity to get your questions answered by the experts.

Sign up now!

Friday Satellite Symposium on Clinical Application of Precision Medicine and New Guidelines in aTTP,” preceding the 63rd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Thank you,
CCO Member Services

Agenda

Welcome, Introduction, and Baseline Assessment

  • Diagnosis and Initial Management of aTTP
  • Management of Relapsed or Refractory aTTP
  • Ongoing Clinical Trials for aTTP
    • Clinical Trial Spotlight: Key Abstracts From ASH 2021

Final Thoughts and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Ara Metjian, MD

Associate Professor
Department of Medicine
University of Colorado
Aurora, CO

Faculty
Paul Coppo, MD, PhD

Professor of Hematology
Sorbonne University
Doctor of Hematology, AP-HP
Paris, France

Faculty
Marshall Mazepa, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with aTTP.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with acquired thrombotic thrombocytopenic purpura.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate appropriate patients to accurately and promptly differentiate acquired TTP from other thrombotic microangiopathies using current guidelines, including ADAMTS13 testing and surrogate scoring systems
  • Discuss the rationale for using VWF targeted therapies as part of the comprehensive management of aTTP
  • Select optimal treatment for patients with newly diagnosed aTTP, including newer therapies in combination with immunosuppression with or without therapeutic plasma exchange
  • Incorporate newer therapies into the management of aTTP based on individual disease characteristics and patient preference
  • Identify patients with aTTP who are eligible for enrollment on a late-phase clinical trial

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.